Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first...

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

•  Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6 •  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa., Jan. 09, 2020 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc....
SEARCH FOR STUDIES